Reports
Sale
Global Exosomes Drug Market Share: By Biomolecule Type: Non-Coding RNAs, mRNA (exoRNA), Proteins/Peptides , DNA Fragments, Lipids; By Product Type: Kits, Reagents, Instruments; By Application: Biomarkers, Drug Delivery System, Others; By Disease Type; Regional Analysis; Challenges and Unmet Need; Supplier Landscape; 2023-2031
Exosomes Drug Market Outlook
The rising cases of cancer have been driving the value of the global exosomes drug market. The number of cancer cases was close to 20.6 million in 2021. The prevalence of cancer diseases is likely to grow at the rate of 6.55% in the forecast period of 2023-2031. With this growth rate, the number of cases is likely to reach nearly 36.4 million by 2030.
Introduction
Exosomes are small membrane vesicles of endocytic origin that are released from various cells in culture and are formed by plasma membrane fusion with the intermediate intracellular compartment and multivesicular body (MVB) fusion.
Exosomes are nano-sized vesicles capable of carrying DNA, small RNA, non-coding RNA, and lipids, with or without direct cell-to-cell communication, representing a new method of cell-to-cell communication.
Exosomes play a vital role in immune responses , viral pathogenicity, pregnancy, cardiovascular disease, central nervous system disease, and cancer progression. Biomolecules, including proteins, metabolites, and nucleic acids, are delivered to target cells by exosomes to adjust biological responses.
Exosomes are designed to deliver variety of therapeutic payloads, including short-interference ribonucleic acids (RNAs), antiallergic oligonucleotides, chemotherapeutic agents, and immunomodulatory agents, and direct their delivery to the desired targets. Liquid biopsy, based on exosome vesicle, can be used to diagnose and determine prognosis in patients with cancer and other diseases. Therefore, the increase in cancer cases in hospitals directly increases the demand for the drugs.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
According to the global exosomes drug market research report, the market can be categorised into the following segments:
Market Breakup by Biomolecule Type
- Non-Coding RNAs
- mRNA (exoRNA)
- Proteins/ Peptides
- DNA Fragments
- Lipids
Market Breakup by Product Type
- Kits
- Reagents
- Instruments
Market Breakup by Application
- Biomarkers
- Drug Delivery System
- Vaccine Development
- Therapeutic Agents
- Others
Market Breakup by Disease Type
- Cancer Disease
- Cardiovascular Disease
- Neurodegenerative Disease
- Tissue Regeneration
- Infectious Disease
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Region
- North America
United States of America
Canada
- Europe
United Kingdom
Germany
France
Italy
Others
- Asia Pacific
China
Japan
India
ASEAN
Australia
Others
- Latin America
Brazil
Argentina
Mexico
Others
- Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others
Market Scenario
The rapid growth of cancer disease drives the growth of the exosomes drug market. The rising demand for advanced drug therapies and potential applications of exosomes in diagnostics are expected to drive the market growth further in the coming years.
The market is primarily driven by the rising cases of cancer, followed by other infectious disease. Advanced exosomes technology in drug development and discovery provides valuable insights into heterogeneity and biological function, enabling us to exploit the therapeutic and diagnostic potential in cancer and infectious diseases. Therefore, the development of medical technology is driving the growth of global exosomes drug market.
The increasing demand for drug therapy in the pharmaceutical and biopharmaceutical fields can be attributed to the potential of exosomes technology as a diagnostic and therapeutic tool used in the treatment of various diseases, such as neurodegeneration, cardiovascular dysfunction, and cancer.
The potential applications of exosomes in cancer diagnostics and the development of precision medicine will increase the use of exosomes in the diagnostic and therapeutic industries, driving the growth of the market.
The rising application of these drugs due to its multifunctional properties has propelled its application in the treatment of various diseases like Alzheimer's disease, chronic heart failure, Parkinson's disease, liver cancer, breast cancer, lung cancer, and prostate cancer.
Regional Outlook for Global Exosomes Drug Market
North America accounted for a significant share of the global market and is expected to grow rapidly during the forecast period. The leading position of the region can be attributed to factors like excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.
On the other hand, the Asia Pacific region is also expected to witness significant growth in the coming years due to the higher presence of the emerging regions and their potential of growth. The regional market is likely to witness further growth due to the competitive strategies that are adopted by players to conduct research and development activities in this sector. Also, the growth of various pharmaceutical companies in this region is another factor that is fuelling the growth of exosomes drug market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Therapeutic Landscape
The exosomes drug market has been growing at a rapid rate owing to its multipurpose uses. Exosomes have been a preferred approach for treatment for various disease, including Alzheimer’s disease and COVID-19, among others. Exosomes find extensive clinical applications in the treatment of various diseases as a cell-free alternative for tissue regeneration using therapeutic cargo components, bypassing immune rejection and cytotoxicity.
Stem cell-derived exosomes help harness the anti-inflammatory and regenerative properties of parent cells. Thus, it is possible to design outpatient treatment of respiratory viral diseases, including SARS-CoV-2.
According to a few research studies, exosomes have generated positive results as mediators of intercellular communication, potentially delivering the functional proteins, mRNA transcripts, and miRNAs to cells throughout the body.
Research on exosomes applications is advancing rapidly, but the development of exosome-based therapy, especially the production of exosome formulations, has many difficulties due to low productivity and heterogeneity. Moreover, there are several barriers to the methods of storage, optimisation, and isolation of exosome formulations.
Clinical Landscape
Exosomes are associated with immune responses, viral pathogenesis, pregnancy, cardiovascular disease, diseases related to the central nervous system and the development of cancer. Exosomes do not only aid the diagnosis of diseases but also have therapeutic potential for controlling many diseases.
ExoFlo is a new clinical drug that has not been approved by the Food and Drug Administration. It is a product of extracellular vesicles isolated from human bone marrow stem cells or stromal cells (MSCs). The drug is in phase 2 of clinical development for the treatment of COVID-19, ARDS, and viral pneumonia.
Progenza is developed by Regeneus and is currently in development stage II for osteoarthritis and preclinical stages for neuropathic pain. Progenza is a cellular therapy that targets pain and inflammation, used to improve the tissues where the Secretome is present, and the Mesenchymal Signaling Cells (MSCs) themselves.
Competitive Landscape
The report gives an in-depth analysis of the key players involved in the global exosomes drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Danaher Corporation (Beckman Coulter Inc.)
- Hologic Inc.
- Lonza Group AG
- Fujifilm Holdings Corporation
- Miltenyi Biotec GmbH
- Qiagen N.V.
- Thermo Fisher Scientific Inc.
- JSR Corporation (MBL International)
- Illumina, Inc.
- Takara Bio Inc.
- Malvern Instruments Ltd. (Spectris Plc Company)
- Abcam Plc.
- Ampersand Capital Partner (New England Peptide, Inc.)
- Evox Therapeutics Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Biomolecule Type |
|
| Breakup by Product Type |
|
| Breakup by Application |
|
| Breakup by Disease Type |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Exosomes Drug Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Exosomes Drug Market
6.1 Global Exosomes Drug Market Overview
6.2 Global Exosomes Drug Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Exosomes Drug Market Historical Value (2016-2022)
6.2.1.2 Global Exosomes Drug Market Forecast Value (2023-2031)
6.3 Global Exosomes Drug Market by Biomolecule Type
6.3.1 Market Overview
6.3.1.1 Non-Coding RNAs
6.3.1.2 mRNA (exoRNA)
6.3.1.3 Proteins/Peptides
6.3.1.4 DNA Fragments
6.3.1.5 Lipids
6.4 Global Exosomes Drug Market by Product Type
6.4.1 Market Overview
6.4.1.1 Kits
6.4.1.2 Reagents
6.4.1.3 Instruments
6.5 Global Exosomes Drug Market by Application
6.5.1 Market Overview
6.5.1.1 Biomarkers
6.5.1.2 Drug Delivery System
6.5.1.3 Vaccine Development
6.5.1.4 Therapeutic Agents
6.5.1.5 Others
6.6 Global Exosomes Drug Market by Disease Type
6.6.1 Market Overview
6.6.1.1 Cancer Disease
6.6.1.2 Neurodegenerative Diseases
6.6.1.3 Cardiovascular Diseases
6.6.1.4 Infectious Diseases
6.6.1.5 Tissue Regeneration
6.6.1.6 Others
6.7 Global Exosomes Drug Market by Region
6.7.1 Market Overview
6.7.1.1 North America
6.7.1.2 Europe
6.7.1.3 Asia Pacific
6.7.1.4 Latin America
6.7.1.5 Middle East and Africa
7 North America Exosomes Drug Treatment Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
7.3 Canada
7.3.1 Historical Trend (2016-2022)
7.3.2 Forecast Trend (2023-2031)
8 Europe Exosomes Drug Treatment Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3 Germany
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4 France
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
8.5 Italy
8.5.1 Historical Trend (2016-2022)
8.5.2 Forecast Trend (2023-2031)
8.6 Others
9 Asia Pacific Exosomes Drug Treatment Market
9.1 Market Share by Country
9.2 China
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Japan
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4 India
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5 ASEAN
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
9.6 Australia
9.6.1 Historical Trend (2016-2022)
9.6.2 Forecast Trend (2023-2031)
9.7 Others
10 Latin America Exosomes Drug Treatment Market
10.1 Market Share by Country
10.2 Brazil
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Argentina
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 Mexico
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Others
11 Middle East and Africa Exosomes Drug Treatment Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 United Arab Emirates
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 Nigeria
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 South Africa
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Others
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Investment Scenarios
12.5 Regulatory Framework
12.5.1 Regulatory Overview
12.5.1.1 US FDA
12.5.1.2 EU EMA
12.5.1.3 INDIA CDSCO
12.5.1.4 JAPAN PMDA
12.5.1.5 Others
13 Challenges and Unmet Need
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Rate
13.3 Awareness and Prevention Gaps
14 Global Exosomes Drug Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter’s Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Danaher Corporation (Beckman Coulter Inc.)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Hologic Inc.
15.2.1 Company Overview
15.2.2 Product portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Lonza Group AG
15.3.1 Company Overview
15.3.2 Product portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Fujifilm Holdings Corporation
15.4.1 Company Overview
15.4.2 Product portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Miltenyi Biotec GmbH
15.5.1 Company Overview
15.5.2 Product portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Qiagen N.V.
15.6.1 Company Overview
15.6.2 Product portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Thermo Fisher Scientific Inc.
15.7.1 Company Overview
15.7.2 Product portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 JSR Corporation (MBL International)
15.8.1 Company Overview
15.8.2 Product portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Illumina, Inc.
15.9.1 Company Overview
15.9.2 Product portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Takara Bio Inc.
15.10.1 Company Overview
15.10.2 Product portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Malvern Instruments Ltd. (Spectris Plc Company)
15.11.1 Company Overview
15.11.2 Product portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Abcam Plc.
15.12.1 Company Overview
15.12.2 Product portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Ampersand Capital Partner (New England Peptide, Inc.)
15.13.1 Company Overview
15.13.2 Product portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Evox Therapeutics Ltd.
15.14.1 Company Overview
15.14.2 Product portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor Pricing Analysis
16.2.2 Key Assessment of Product Attributes
16.2.3 Pricing Benchmark
17 Global Exosomes Drug Market- Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The rising prevalence of cancer cases is driving the demand for exosome drugs. The prevalence of cancer cases is likely to grow at the rate of 6.55% during the forecast period of 2023-2031.
The rise in demand for drug therapy in the pharmaceutical and biopharmaceutical field is fuelled by the potential of exosome technology as a diagnostic and therapeutic tool used in the treatment of various diseases, such as neurodegeneration, cardiovascular dysfunction, and cancer.
Based on the product type, the market can be segmented into kits, reagents, and instruments.
Based on the application, the market can be segmented into biomarkers, drug delivery system, vaccine development, therapeutic agents, and others.
Based on the disease type, the market can be fragmented into cancer disease, neurodegenerative disease, cardiovascular disease, infectious disease, tissue regeneration, and others.
The major regions in the industry are North America, Latin America, the Middle East, Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market .
North America is expected to dominate the market due to excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.
Danaher Corporation (Beckman Coulter Inc.), Hologic Inc., Lonza Group AG, Fujifilm Holdings Corporation, Miltenyi Biotec GmbH, Qiagen N.V., Thermo Fisher Scientific Inc., JSR Corporation (MBL International), Illumina, Inc., Takara Bio Inc., Malvern Instruments Ltd. (Spectris Plc Company), Abcam Plc., Ampersand Capital Partner (New England Peptide, Inc.), and Evox Therapeutics Ltd. are the top companies in the exosome drug market.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER